Stablizing An Enzyme By Forming A Mixture, An Adduct Or A Composition, Or Formation Of An Adduct Or Enzyme Conjugate Patents (Class 435/188)
  • Antibody Specific for CD22 and Methods of Use Thereof
    Publication number: 20140161870
    Abstract: The present disclosure provides antibodies specific for an epitope present on CD22. The antibodies are useful in various treatment, diagnostic, and monitoring applications, which are also provided.
    Type: Application
    Filed: July 15, 2013
    Publication date: June 12, 2014
    Inventors: David Rabuka, Robert George Edward Holgate, Francis Joseph Carr
  • SYNTHETIC HEPATITIS C GENOME AND METHODS OF MAKING AND USE
    Publication number: 20140162340
    Abstract: Synthetic representative HCV subtypes, including a 1a and 1b genome, dubbed Bole1a and Bole1b, are provided using an inventive method of Bayesian phylogenetic tree analysis, ancestral sequence reconstruction and covariance analysis. Bole1a branches centrally among 390 full-genome sequences used in its design, a carefully curated 143 sequence full-genome dataset, and separate genomic regions including an independent set of 214 E1E2 sequences from a Baltimore cohort. Bole1a is phylogenetically representative of widely circulating strains. Full genome non-synonymous diversity comparison and 9-mer peptide coverage analysis showed that Bole1a is able to provide more coverage (94% and 78% respectively) than any other sequence in the dataset including H77, a traditional reference sequence. Bole1a also provides unsurpassed epitope coverage when compared to all known T cell epitopes.
    Type: Application
    Filed: May 2, 2012
    Publication date: June 12, 2014
    Inventors: Stuart Campbell Ray, Supriya Munshaw, Lin Liu
  • Methods of Modulating Vesicular Trafficking
    Publication number: 20140162285
    Abstract: Described are methods of identifying compounds useful for modulating vesicular trafficking, particularly those that disrupt the interactions between ARNO and the V-ATPase a2-subunit. Also described are peptides that modulate vesicular trafficking.
    Type: Application
    Filed: December 2, 2013
    Publication date: June 12, 2014
    Applicant: The General Hospital Corporation
    Inventors: Vladimir Marshansky, Maria Merkulova
  • AMPHIPATHIC PEPTIDE-LIPASE CONJUGATE HAVING ADVANCED LIPASE ACTIVITY AND USE THEREOF
    Publication number: 20140162331
    Abstract: Disclosed are an amphipathic peptide-lipase conjugate with enhanced lipase activity, a polynucleotide coding for the conjugate, an expression vector carrying the polynucleotide, a transformant anchoring the expression vector therein, a method for preparing the conjugate, a lipolysis method using the conjugate, and a method for producing biodiesel using the lipase.
    Type: Application
    Filed: August 10, 2012
    Publication date: June 12, 2014
    Inventors: Sun-Chang Kim, Bong Hyun Sung, Kyung Seok Yang, Jun Hyoung Lee, Ki Jung Lim, Myung Keun Park
  • Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using The Same
    Publication number: 20140154203
    Abstract: The present invention relates, in part, to a biocompatible hydrophobic-core carrier comprising a carrier, and a plurality of hydrophobic groups covalently linked to the polymeric carrier. The hydrophobic groups are capable of dissociably linking load molecules such as therapeutic agents. The hydrophobic-core carrier may also comprise protective side chains, orienting molecules, and targeting molecules.
    Type: Application
    Filed: November 22, 2013
    Publication date: June 5, 2014
    Applicant: PharmaIN Corporation
    Inventors: Gerardo M. Castillo, Elijah M. Bolotin
  • NPP1 FUSION PROTEINS
    Publication number: 20140154774
    Abstract: The present invention provides a novel fusion polypeptide containing a catalytic domain of NPP1 fused to a targeting moiety, nucleic acids encoding the fusion polypeptide, a vector containing the nucleic acid integrated thereinto, a host cell transformed with the vector and pharmaceutical compositions comprising the fusion polypeptide.
    Type: Application
    Filed: September 15, 2011
    Publication date: June 5, 2014
    Applicant: Synageva Biopharma Corp.
    Inventors: Anthony Quinn, Alex J. Harvey, Zhinan Xia
  • PHOTOCLEAVABLE LINKER
    Publication number: 20140154775
    Abstract: There are provided, inter alia, photolabile compounds and methods useful for the formation of dimers of biological molecules and subsequent dissociation of the dimers.
    Type: Application
    Filed: November 19, 2013
    Publication date: June 5, 2014
    Applicant: City of Hope
    Inventors: John C. Williams, David Horne, Jun Xie, Shubbir Ahmed
  • Glycopegylated Factor IX
    Publication number: 20140154230
    Abstract: Conjugates between Factor IX and PEG moieties. are disclosed in the present application. The conjugates are linked via a glycosyl linking group interposed between and covalently attached to the peptide and the modifying group. Conjugates are formed from glycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar moiety onto a glycosyl residue on the peptide. Also provided are methods for preparing the conjugates, methods for treating various disease conditions with the conjugates, and pharmaceutical formulations including the conjugates.
    Type: Application
    Filed: October 17, 2013
    Publication date: June 5, 2014
    Applicant: Novo Nordisk A/S
    Inventors: Shawn DeFrees, Robert J. Bayer, Caryn Bowe, Panneerselvam Krishnasamy
  • SELECTIVELY TARGETED ANTIMICROBIAL PEPTIDES AND THE USE THEREOF
    Publication number: 20140155317
    Abstract: The present invention relates to targeting peptides capable of specifically binding to microbial organisms (e.g., P. aeruginosa or S. mutans), antimicrobial peptides having antimicrobial activities, and specifically/selectively targeted antimicrobial peptides (STAMPs). In addition, the present invention provides methods of selectively killing or inhibiting microbial organisms by using the peptides or compositions provided by the present invention.
    Type: Application
    Filed: February 11, 2014
    Publication date: June 5, 2014
    Applicants: C3 JIAN, INC., THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Randal H. Eckert, Daniel K. Yarbrough, Wenyuan Shi, Maxwell H. Anderson, Fengxia Qi, Jian He, Ian H. McHardy
  • Compositions and Methods for Detecting Vitamin D
    Publication number: 20140154700
    Abstract: Compounds include carbamate derivatives of vitamin D including vitamin D3 and vitamin D2. The compounds are useful in methods and kits for determining the presence and/or amount of vitamin D including vitamin D analogs and metabolites thereof in a sample suspected of containing the same.
    Type: Application
    Filed: November 30, 2012
    Publication date: June 5, 2014
    Inventors: Zhu Teng, Roland Janzen, Martin A. Drinan
  • Stable Lysis Buffer Mixture for Extracting Nucleic Acids
    Publication number: 20140154776
    Abstract: Embodiments relate to a lysis buffer mixture that is stable in storage for isolating nucleic acids from biological, preferably diagnostic samples. The mixture is preferably associated with an extraction control. The aim of the invention is to provide an improved nucleic acid extraction system, which is cost-effective, stable and easy to use, thus fulfilling the requirements of a modern nucleic acid extraction system and containing, among other things, extraction controls. Embodiments relate to a lysis buffer mixture for isolating nucleic acids, said mixture containing non chaotropic salts, a special selection of detergents, a defined quantity of at least one nucleic acid as an extraction control, optionally lytic enzymes, optionally carrier nucleic acids and optionally other additives.
    Type: Application
    Filed: February 3, 2014
    Publication date: June 5, 2014
    Inventors: Peter Bendzko, Hans Joos
  • THROMBIN SOLUTION AND METHODS OF USE THEREOF
    Publication number: 20140154773
    Abstract: Provided are methods for lyophilization of an aqueous thrombin solution, thrombin solutions for use in such lyophilization methods, and solid thrombin compositions produced by such methods.
    Type: Application
    Filed: March 4, 2013
    Publication date: June 5, 2014
    Inventors: Roberto Meidler, Oleg Belyaev, Liliana Bar, Israel Nur
  • CROSS-LINKED POLY-E-LYSINE PARTICLES
    Publication number: 20140154737
    Abstract: The invention provides a cross-linked poly-?-lysine polymer. The poly-?-lysine and cross linker are linked by amide bonds and may the cross linker has at least two functional groups capable of reacting with an alpha carbon amine of poly-?-lysine. The polymer is suitably insoluble in water and other solvents and is provided in particulate form. The invention provides a particulate support comprising the cross-linked poly-?-lysine polymer and the polymer may provide the particle itself or be coated on a particle for example silica. The polymer is useful in a wide range of applications including wound treatment, as a medical diagnostic comprising a particulate support and a functional material bound or retained by the support and solid phase synthesis of peptides, oligonucleotides, oligosaccharides, immobilisation of species, cell culturing and in chromatographic separation.
    Type: Application
    Filed: April 20, 2012
    Publication date: June 5, 2014
    Applicant: SPHERITECH LTD
    Inventor: Donald Wellings
  • MONOCLONAL ANTIBODIES SPECIFIC FOR BETA-AMYLOID X-37 AND USES THEREOF
    Publication number: 20140154715
    Abstract: The present invention provides monoclonal antibodies which specifically recognize the shorter A? peptides obtained after cleavage of the APP protein mediated by ?-secretase, i.e. the A?-peptide fragments A?1-37, A?3-37, A?3p-37, A?1-37 and A?11p-37, and other like fragments ending at the 37th amino acid of APP, hereinafter also referred to as the A?x-37 peptides. It further provides hybridoma cells producing the monoclonal antibodies as well as methods for producing the antibodies and the hybridoma cells; and an immunoassay for an A?x-37 peptide by a competitive method or a sandwich method using the antibody of the present invention; and methods for measuring the level of A?x-37 peptides in a sample, such as a biological sample.
    Type: Application
    Filed: July 6, 2012
    Publication date: June 5, 2014
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: Marc Hubert Mercken, Marianne Borgers, Marc, Maria, Pierre, Pelagie Vandermeeren, Bianca Julia J Van Broeck
  • METHODS AND COMPOSITIONS FOR DETECTING AND MODULATING A NOVEL MTOR COMPLEX
    Publication number: 20140157443
    Abstract: Provided herein is a novel mTOR-comprising complex, mT-ORC3, which comprises mTOR and the Ets transcription factor TEL2. Specific mTORC3 binding agents and modulating agents are provided, along with kits and methods for the detection of mTORC3. Methods of modulating the activity of mTORC3 or modulating cell growth and/or survival are also provided. Further provided are methods for screening for mTORC3 binding agents and for mTORC3 modulating agents. Various methods of diagnosis and treatment are further provided.
    Type: Application
    Filed: April 12, 2012
    Publication date: June 5, 2014
    Applicant: ST. JUDE CHILDREN'S RESEARCH HOSPITAL
    Inventors: Gerard C. Grosveld, Frank C. Harwood, Ramon I. Klein-Geltink
  • Compositions and Methods for Making Selenocysteine Containing Polypeptides
    Publication number: 20140154744
    Abstract: Non-naturally occurring tRNASec and methods of using them for recombinant expression of proteins engineered to include one or more selenocysteine residues are disclosed. The non-naturally occurring tRNASec can be used for recombinant manufacture of selenocysteine containing polypeptides encoded by mRNA without the requirement of an SECIS element. In some embodiments, selenocysteine containing polypeptides are manufactured by co-expressing a non-naturally occurring tRNASec a recombinant expression system, such as E. coli, with SerRS, EF-Tu, SelA, or PSTK and SepSecS, and an mRNA with at least one codon that recognizes the anticodon of the non-naturally occurring tRNASec.
    Type: Application
    Filed: July 11, 2012
    Publication date: June 5, 2014
    Applicant: YALE UNIVERSITY
    Inventors: Dieter Soll, Caroline Aldag, Michael Hohn
  • Magnetic nanoparticle with biocompatibility
    Patent number: 8741615
    Abstract: A magnetic nanoparticle is provided in the disclosure. The magnetic nanoparticle includes a magnetic nanoparticle; a biocompatible polymer of the following formula (II) covalently coupled to the magnetic nanoparticle, wherein R1 is alkyl, aryl, carboxyl, or amino; n is an integer from 5 to 1000; and m is an integer from 1 to 10.
    Type: Grant
    Filed: August 30, 2012
    Date of Patent: June 3, 2014
    Assignee: Industrial Technology Research Institute
    Inventors: Wen-Hsiang Chang, Wen-Uan Hsieh, Shiu-Hua Huang, Chin-I Lin, Shian-Jy Jassy Wang, Kelly Teng
  • VARIANT CBH I POLYPEPTIDES WITH REDUCED PRODUCT INHIBITION
    Publication number: 20140147894
    Abstract: The present disclosure relates to variant CBH I polypeptides that have reduced product inhibition, and compositions, e.g., cellulase compositions, comprising variant CBH I polypeptides. The variant CBH I polypeptides and related compositions can be used in variety of agricultural and industrial applications. The present disclosure further relates to nucleic acids encoding variant CBH I polypeptides and host cells that recombinantly express the variant CBH I polypeptides.
    Type: Application
    Filed: October 6, 2011
    Publication date: May 29, 2014
    Applicant: BP Corporation North America Inc.
    Inventors: Justin T. Stege, Alexander Varvak, John Poland, Chris S. Lyon, Shaun Healey, Peter Luginhuhl
  • ANTIBODY CONJUGATES
    Publication number: 20140147906
    Abstract: Antibody/signal-generating moiety conjugates are disclosed that include an antibody covalently linked to a signal-generating moiety through a heterobifunctional polyalkyleneglycol linker. The disclosed conjugates show exceptional signal-generation in immunohistochemical and in situ hybridization assays on tissue sections and cytology samples. In one embodiment, enzyme-metallographic detection of nucleic acid sequences with hapten-labeled probes can be accomplished using the disclosed conjugates as a primary antibody without amplification.
    Type: Application
    Filed: January 2, 2014
    Publication date: May 29, 2014
    Applicant: Ventana Medical Systems, Inc.
    Inventors: Christopher Bieniarz, Jennifer Wong, Mark Lefever, Jerome W. Kosmeder, II, Julia Ashworth-Sharpe, Casey A. Kernag
  • COMPUTATIONALLY OPTIMIZED BROADLY REACTIVE ANTIGENS FOR H1N1 INFLUENZA
    Publication number: 20140147459
    Abstract: Described herein is the generation of optimized H1N1 influenza HA polypeptides for eliciting a broadly reactive immune response to H1N1 influenza virus isolates. The optimized HA polypeptides were developed through a series of HA protein alignments, and subsequent generation of consensus sequences, based on selected H1N1 viruses isolated from 1918-2012. Provided herein are optimized H1N1 HA polypeptides, and compositions, fusion proteins and VLPs comprising the HA polypeptides. Further provided are codon-optimized nucleic acid sequences encoding the HA polypeptides. Methods of eliciting an immune response against influenza virus in a subject are also provided by the present disclosure.
    Type: Application
    Filed: November 27, 2013
    Publication date: May 29, 2014
    Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Ted M. Ross, Corey J. Crevar, Donald M. Carter, JR.
  • GUANYLYLCYCLASE C LIGANDS
    Publication number: 20140147380
    Abstract: Guanylin cyclase C compound of the inventions are disclosed. Conjugated compounds comprising guanylin cyclase C compound of the inventions conjugated to detectable or therapeutic moieties are disclosed. Methods of detecting, imaging and treating cancer and treating diarrhea are disclosed.
    Type: Application
    Filed: October 18, 2013
    Publication date: May 29, 2014
    Applicant: Thomas Jefferson University
    Inventors: Hank Wolfe, Scott A. Waldman
  • Polypeptides Having Endoglucanase Activity And Polynucleotides Encoding Same
    Publication number: 20140150137
    Abstract: The present invention relates to isolated polypeptides having endoglucanase activity, catalytic domains, cellulose binding domains and polynucleotides encoding the polypeptides, catalytic domains or cellulose binding domains. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides, catalytic domains or cellulose binding domains.
    Type: Application
    Filed: April 26, 2012
    Publication date: May 29, 2014
    Applicant: Novozymes, Inc.
    Inventors: Nikolaj Spodsberg, Brett McBrayer, Pierre Cassland
  • THERAPEUTIC FUSION PROTEINS
    Publication number: 20140147429
    Abstract: The present invention relates to the construction of a new class of Targeted Secretion Inhibitors (TSIs), which comprise a non-cytotoxic protease, translocation peptide and a targeting moiety peptide, wherein the targeting moiety peptide has a free N-terminal domain and a free C-terminal domain; to a single-chain fusion protein precursor thereof, and to a method of activating said single-chain fusion protein precursor.
    Type: Application
    Filed: May 16, 2012
    Publication date: May 29, 2014
    Applicant: SYNTAXIN LIMITED
    Inventors: John Chaddock, Elaine Harper
  • Xylanase composition with increased stability
    Patent number: 8735118
    Abstract: A xylanase composition and a method for manufacturing the xylanase composition are provided, wherein the xylanase composition comprises a xylanase and a stabilizer, and the xylanase is from an anaerobic fungus, the stabilizer comprises a polyol, and the content of the polyol is at least 40 wt %, based on the total weight of the xylanase composition.
    Type: Grant
    Filed: November 24, 2009
    Date of Patent: May 27, 2014
    Assignee: YFY Biopulp Technology Limited
    Inventors: Yahui Huang, Chunhui Hsieh, Hsuanyu Lai
  • Perhydrolase variant providing improved specific activity
    Patent number: 8735125
    Abstract: An acetyl xylan esterase variant having perhydrolytic activity is provided for producing peroxycarboxylic acids from carboxylic acid esters and a source of peroxygen. More specifically, a Thermotoga maritima acetyl xylan esterase gene was modified using error-prone PCR and site-directed mutagenesis to create an enzyme catalyst characterized by an increase in specific activity. The variant acetyl xylan esterase may be used to produce peroxycarboxylic acids suitable for use in a variety of applications such as cleaning, disinfecting, sanitizing, bleaching, wood pulp processing, and paper pulp processing applications.
    Type: Grant
    Filed: October 22, 2012
    Date of Patent: May 27, 2014
    Assignee: E. I. du Pont de Nemours and Company
    Inventors: Robert Dicosimo, Mark Scott Payne, John Edward Gavagan
  • Surfactant composition with a reduction of surface tension, interfacial tension, and critical micelle concentration using a protein-based surfactant synergist
    Patent number: 8735338
    Abstract: Surfactant-containing compositions are described which include a protein component that has the effect of improving the surface-active properties of the surfactants contained in the compositions. The surfactant-containing compositions having the protein component demonstrate significantly lower critical micelle concentrations (CMC), reduced surface tensions, and reduced interfacial tensions than do comparable compositions having no protein component. In addition, the surfactant-containing compositions having the protein component has the effect of converting greasy waste contaminants to surface active materials.
    Type: Grant
    Filed: May 29, 2012
    Date of Patent: May 27, 2014
    Assignee: Advanced Biocatalytics Corp.
    Inventors: John W. Baldridge, Carl W. Podella
  • POLYPEPTIDES ISOLATED FROM BREVIBACTERIUM AURANTIACUM AND THEIR USE FOR THE TREATMENT OF CANCER
    Publication number: 20140140978
    Abstract: The present invention relates to methods and pharmaceutical compositions for treating cancer. More specifically, the invention relates to a polypeptide isolated from Brevibacterium aurantiacum that shows methionine gamma-lyase and homocysteinase activities. The present invention also relates to the use of such a polypeptide for the treatment of cancer.
    Type: Application
    Filed: June 15, 2012
    Publication date: May 22, 2014
    Applicants: INSERM (Institut National de la Sante et de la Recherche Medicale), UNIVERSITE PARIS SUD-PARIS XI, INRA (Institut National de la Recherche Agronomique)
    Inventors: David Machover, Pascal Bonnarme
  • Cationic Polymer Based Wired Enzyme Formulations for Use in Analyte Sensors
    Publication number: 20140141487
    Abstract: Embodiments of the invention include analyte-responsive compositions and electrochemical analyte sensors having a sensing layer that includes an analyte-responsive enzyme and a cationic polymer. Also provided are systems and methods of making the sensors and using the electrochemical analyte sensors in analyte monitoring.
    Type: Application
    Filed: January 27, 2014
    Publication date: May 22, 2014
    Applicant: Abbott Diabetes Care Inc.
    Inventors: Benjamin J. Feldman, Tianmei Ouyang, Zenghe Liu
  • Activated Sialic Acid Derivatives For Protein Derivatisation And Conjugation
    Publication number: 20140141486
    Abstract: Derivatives of PSAs are synthesised, in which a reducing and/or non-reducing end terminal sialic acid unit is transformed into a N-hydroxysuccinimide (NHS) group. The derivatives may be reacted with substrates, for instance substrates containing amine or hydrazine groups, to form non-cross-linked/crosslinked polysialylated compounds. The substrates may, for instance, be therapeutically useful drugs, peptides or proteins or drug delivery systems.
    Type: Application
    Filed: January 24, 2014
    Publication date: May 22, 2014
    Applicant: Lipoxen Technologies Limited
    Inventors: Sanjay Jain, Ioannis Papaioannou, Smita Thobhani
  • POLYMER FACTOR IX MOIETY CONJUGATES
    Publication number: 20140141483
    Abstract: Conjugates of a Factor IX moiety and one or more water-soluble polymers are provided. Typically, the water-soluble polymer is polyethylene glycol) or a derivative thereof. Also provided (among other things) are compositions comprising the conjugates, methods of making the conjugates, and methods of administering to a patient compositions comprising the conjugates.
    Type: Application
    Filed: November 8, 2013
    Publication date: May 22, 2014
    Applicant: Nektar Therapeutics
    Inventors: Mary J. Bossard, Gayle Stephenson
  • SERINE PROTEASE MOLECULES AND THERAPIES
    Publication number: 20140140976
    Abstract: Cell-targeted serine protease constructs are provided. Such constructs can be used in methods for targeted cell killing such as for treatment cell of proliferative diseases (e.g., cancer). In some aspects, recombinant serine proteases, such as Granzyme B polypeptides, are provided that exhibit improved stability and cell toxicity. Methods and compositions for treating lapatinib or trastuzumab-resistant cancers are also provided.
    Type: Application
    Filed: October 4, 2013
    Publication date: May 22, 2014
    Applicant: RESEARCH DEVELOPMENT FOUNDATION
    Inventors: Michael G. ROSENBLUM, Khalid Amanali MOHAMEDALI, Lawrence H. CHEUNG
  • TYROSINE LIGATION PROCESS
    Publication number: 20140141034
    Abstract: A process is provided for preparing a conjugate of Formula (I-A) or (I) comprising a polypeptide containing n number of tyrosine units, where n is an integer greater than or equal to 1, dispersed within the amino acid chain having and amino terminus end (A1) and an acid terminus end (A2) of the protein or polypeptide and having a weight average molecular weight equal to or greater than 10,000 Daltons (10 kDa), wherein the conjugate comprises a number m of tyrosine conjugates (modified tyrosine residues) as depicted in Formula (I-A) or (I), where m is at least one and is less than or equal to n: where X, Lg, L and R are as defined herein.
    Type: Application
    Filed: July 5, 2012
    Publication date: May 22, 2014
    Applicant: NOVARTIS AG
    Inventors: Roberto Adamo, Martin Allen, Francesco Berti, Elisa Danieli, Qi-Ying Hu
  • ZCYTOR17 HETERODIMERIC CYTOKINE RECEPTOR
    Publication number: 20140141485
    Abstract: Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17-containing multimeric or heterodimer cytokine receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. The present invention also includes methods for producing the multimeric or heterodimeric cytokine receptor, uses therefor and antibodies thereto.
    Type: Application
    Filed: December 23, 2013
    Publication date: May 22, 2014
    Applicant: ZymoGenetics, Inc.
    Inventors: Cindy A. Sprecher, Joseph L. Kuijper, Maria M. Dasovich, Francis J. Grant, Theodore E. Whitmore, Angela K. Hammond, Julia E. Novak, Jane A. Gross, Stacey R. Dillon
  • Multiple Hybrid Immunoassay
    Publication number: 20140141484
    Abstract: The invention relates to compositions and methods for the immunoassay of an analyte of interest. The analyte is detected in an immunoassay using three or more antibodies, wherein each antibody specifically binds to a different epitope on the analyte. When the analyte of interest in a clinical marker for an acute disease, the detection of the analyte by immunoassay is a diagnosis of the occurrence of the disease.
    Type: Application
    Filed: November 15, 2013
    Publication date: May 22, 2014
    Applicant: Abbott Point of Care Inc.
    Inventors: John Lewis Emerson Campbell, Pamela Anne Frank, Meghan Elizabeth Hawkes, Shannon Reishma Lobin, Cary James Miller, Zhen Yang
  • TEM8 ANTIBODIES, CONJUGATES THEREOF, AND THEIR USE
    Publication number: 20140134179
    Abstract: Antibodies that specifically bind TEM8 protein, and conjugates thereof, are disclosed herein. In some examples the conjugates and antibodies are useful for methods of detecting and treating pathogenic angiogenesis. In other examples the conjugates and antibodies are useful for methods of detecting and treating cancer. In additional examples, the conjugates and antibodies are useful for methods of decreasing binding of Anthrax protective antigen to a cell.
    Type: Application
    Filed: June 13, 2012
    Publication date: May 15, 2014
    Applicants: Novartis AG, The United States of America, as represented by the Sec., Dept of Health and Human Services
    Inventors: Brad St. Croix, Tony Fleming, Amit Chaudhary, Saurabh Saha, Xiaoyan Michelle Zhang, Rou-fun Kwong
  • Stable Discrete PEG Based Peroxidase Biological Conjugates
    Publication number: 20140134651
    Abstract: Disclosed is an analytical composition of a peroxidase discrete polyethylene glycol (PEG) conjugate, which conjugate is capable of providing a detectable condition in the presence of peroxidase and hydrogen peroxide.
    Type: Application
    Filed: December 3, 2013
    Publication date: May 15, 2014
    Applicant: QUANTA EQIP, LLC
    Inventors: Paul D. Davis, Alexander R. Pokora
  • Compositions for Diagnosis and Therapy of Diseases Associated with Aberrant Expression of Futrins (R-Spondins) and/or Wnt
    Publication number: 20140134703
    Abstract: The present invention relates to a composition useful for the diagnosis of diseases associated with aberrant expression of the genes encoding the secreted proteins Futrin 1, 2, 3 and/or 4 (=R-Spondin 2, 3, 1 and 4, respectively), e.g. in connection with tumors or diseases of the muscle, kidneys or bones. The present invention also relates to a pharmaceutical composition containing a compound which is capable of modifying (a) the expression of the gene encoding Futrin 1, 2, 3 and/or 4 or (b) the activity of the Futrin 1, 2, 3 and/or 4 protein.
    Type: Application
    Filed: July 19, 2013
    Publication date: May 15, 2014
    Applicant: Deutsches Krebsforschungszentrum
    Inventors: Christof Niehrs, Wei Wu, Andrey Glinka, Olga Kazanskaya
  • NOVEL DNA-BINDING PROTEINS AND USES THEREOF
    Publication number: 20140134740
    Abstract: Disclosed herein are polypeptides, polynucleotides encoding, cells and organisms comprising novel DNA-binding domains, including TALE DNA-binding domains. Also disclosed are methods of using these novel DNA-binding domains for modulation of gene expression and/or genomic editing of endogenous cellular sequences.
    Type: Application
    Filed: October 28, 2013
    Publication date: May 15, 2014
    Applicant: Sangamo BioSciences, Inc.
    Inventors: Philip D. Gregory, Jeffrey C. Miller, David Paschon, Edward J. Rebar, Siyuan Tan, Fyodor Urnov, Lei Zhang
  • Respiratory Syncytial Virus (RSV) Sequences For Protein Expression and Vaccines
    Publication number: 20140134203
    Abstract: The invention provides RSV fusion (F) protein ectodomain polypeptide sequences and nucleotide sequences encoding them, as well as cells containing the invention's polypeptide and nucleotide sequences. The invention further provides VLPs that contain the invention's polypeptides, and methods for using the VLPs for protein expression and vaccine formulation. Also provided are methods for distinguishing between subjects immunized with the invention's compositions and subjects infected with RSV.
    Type: Application
    Filed: November 8, 2013
    Publication date: May 15, 2014
    Applicant: University of Massachusetts
    Inventor: Trudy Morrison
  • Solubilized Phospholipids for Stabilizing Nucleic Acid Polymerases
    Publication number: 20140134702
    Abstract: Compositions and methods are provided that relate to solubilized phospholipids and their use in stabilizing nucleic acid polymerases. For example, a phospholipid with a tail containing at least 8 carbons can be solubilized in the presence of an amphipathic molecule.
    Type: Application
    Filed: April 19, 2012
    Publication date: May 15, 2014
    Applicant: NEW ENGLAND BIOLABS, INC.
    Inventors: Donald Johnson, Thomas C. Evans, JR.
  • N-TERMINAL DERIVATISATION OF PROTEINS WITH POLYSACCHARIDES
    Publication number: 20140134147
    Abstract: The present invention relates to methods for producing N-terminal derivatives of proteins in which a polysaccharide, preferably having at least terminal sialic units and preferably consisting essentially only of sialic acid units, is reacted at the N-terminus of a protein or peptide under controlled conditions to produce an N-terminal derivative. The controlled conditions include use of acidic pH for the derivatisation step and a higher pH for purification. The derivatives are useful for improving pharmacokinetics and pharmacodynamics of proteins and peptides.
    Type: Application
    Filed: March 11, 2013
    Publication date: May 15, 2014
    Applicant: Lipoxen Technologies Limited
    Inventor: Lipoxen Technologies Limited
  • P97 fragments with transfer activity
    Patent number: 8722019
    Abstract: The present invention is related to fragments of human melanotransferrin (p97). In particular, this invention relates to treatment of diseases through the introduction of the melanotransferrin fragment conjugated to a therapeutic or diagnostic agent to a subject.
    Type: Grant
    Filed: August 3, 2012
    Date of Patent: May 13, 2014
    Assignee: biOasis Technologies, Inc.
    Inventors: Wilfred Jefferies, Mei Mei Tian, Timothy Vitalis
  • MANUFACTURING METHOD FOR SILICA ENCAPSULATED SINGLE-ENZYME NANOPARTICLES AND SINGLE-ENZYME NANOPARTICLES MANUFACTURED BY MEANS OF METHOD
    Publication number: 20140127778
    Abstract: A method for manufacturing single enzyme nanoparticles through silica encapsulation according to the present disclosure does not include a surface functionalization process and a polymerization process during the synthesis, and reaction conditions are mild. Thus, the method is appropriate for a large scale production.
    Type: Application
    Filed: May 23, 2012
    Publication date: May 8, 2014
    Applicant: KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION
    Inventors: Jungbae Kim, Sung-Gil Hong, Byoungsoo Lee
  • MUTANT CYTOCHROME P450 2B6 PROTEINS AND USES THEREOF
    Publication number: 20140127180
    Abstract: The present invention to relates mutant human cytochrome P450 2B6 (CYP2B6) proteins, and fusion proteins comprising said mutant CYP2B6 proteins. In particular, fusion proteins comprising mutant CYP2B6 and NAPDH-cytochrome P450 reductase are provided. The invention also relates to methods of treatment of cancer and the use of said proteins and fusion proteins in the treatment of cancer, in particular via virus-directed enzyme prodrug therapy.
    Type: Application
    Filed: May 4, 2012
    Publication date: May 8, 2014
    Applicant: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Isabelle De Waziers, Walid Touati, Monique Diry, Jean-Pierre Flinois, Patrick Dansette, Philippe Beaune
  • IDENTIFICATION OF SECRETED PROTEINS AS DETECTION MARKERS FOR CITRUS DISEASE
    Publication number: 20140127718
    Abstract: Secreted proteins as detection markers for insect vector and graft transmitted citrus disease are described. Method and kits for detecting the secreted proteins are provided.
    Type: Application
    Filed: March 14, 2013
    Publication date: May 8, 2014
    Applicant: The Regents of the University of California
    Inventor: The Regents of the University of California
  • METHOD FOR STABILIZATION OF PROTEINS USING NON-NATURAL AMINO ACIDS
    Publication number: 20140127777
    Abstract: The present invention provides a method for producing modified stable polypeptides introducing at least one non-natural amino acid into the hydrophobic region of the polypeptide. The thermal and chemical stability of such polypeptides is improved compared to those properties of its corresponding wild type proteins. The invention further provides purified leucine zipper and coiled-coil proteins in which the leucine residues have been replaced with 5,5,5-trifluoroleucines, and the modified proteins so produced demonstrate increased thermal and chemical stability compared to their corresponding wild-type natural proteins.
    Type: Application
    Filed: October 29, 2013
    Publication date: May 8, 2014
    Applicant: CALIFORNIA INSTITUTE OF TECHNOLOGY
    Inventors: David A. Tirrell, Yi Tang
  • DIMERIC BINDING PROTEINS BASED ON MODIFIED UBIQUITINS
    Publication number: 20140127129
    Abstract: The present invention refers to novel dimeric proteins obtained from modified ubiquitin capable of binding targets with high affinity. The novel dimeric binding proteins comprise a combination of amino acid substitutions and at least one insertion of amino acids in one of the monomers. The invention is further directed to the use of said proteins in medical diagnosis or treatment methods.
    Type: Application
    Filed: June 15, 2012
    Publication date: May 8, 2014
    Applicant: Scil Proteins GmbH
    Inventors: Joerg Nerkamp, Eva Bosse-Doenecke, Arnd Steuernagel, Ulrike Fiedler, Markus Fiedler
  • ENZYMES FOR STARCH PROCESSING
    Publication number: 20140127753
    Abstract: The present invention relates to polypeptides comprising a carbohydrate-binding module amino acid sequence and an alpha-amylase amino acid sequence as well as to the application of such polypeptides.
    Type: Application
    Filed: November 2, 2012
    Publication date: May 8, 2014
    Inventors: Shiro Fukuyama, Tomoko Matsui, Chee Leong Soong, Eric Allain, Anders Vikso Nielsen, Hiroaki Udagawa, Ye Liu, Junxin Duan, Wenping Wu, Lene Nonboe Andersen
  • Fractionation of Charged Polysaccharide
    Publication number: 20140127779
    Abstract: Polydisperse and charged polysaccharides are fractionated into low polydispersity fractions (preferably having pd<1.1), each containing species within a narrow range of molecular weights. An aqueous solution of the polydisperse polysaccharides is contacted with an ion exchange resin in a column and the polysaccharides are subjected to selective elution by aqueous elution buffer. The selective elution consists of at least 3 sequential elution buffers having different and constant ionic strength and/or pH and in which the subsequent buffers have ionic strength and/or pH than those of the preceding step. The new preparations are particularly suitable for the production of PSA-derivatised therapeutic agents intended for use in humans and animals.
    Type: Application
    Filed: January 15, 2014
    Publication date: May 8, 2014
    Applicant: Lipoxen Technologies Limited
    Inventors: Sanjay Jain, Ioannis Papaioannou, Peter Laing
  • Methods of Increasing the Cellulolytic Enhancing Activity of a Polypeptide
    Publication number: 20140127771
    Abstract: The present invention relates to methods of increasing the activity of a GH61 polypeptide having cellulolytic enhancing activity, comprising: adding a divalent copper cation to a composition comprising the GH61 polypeptide having cellulolytic enhancing activity, wherein the presence of the divalent copper cation and the GH61 polypeptide having cellulolytic enhancing activity increases degradation or conversion of a cellulosic material by an enzyme composition compared to the GH61 polypeptide having cellulolytic enhancing activity without the divalent copper cation. The present invention also relates to compositions, methods for degrading or converting a cellulosic material, and methods for producing a fermentation product.
    Type: Application
    Filed: March 9, 2012
    Publication date: May 8, 2014
    Applicants: Novozymes, Inc., Novozymes A/S
    Inventors: Katja Salomon Johansen, Feng Xu, Paul Walton, Brett McBrayer, Henrik Lund, Chee-Leong Soong